Senolytic Protocol for Reversing Epigenetic Aging

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods to address aging, such as extending telomeres or using fullerenes, ultimately lead to increased epigenetic age as they fail to effectively manage stem cell pools and senescent cell accumulation, resulting in continued cellular dysfunction and aging.

Innovation Solution

The protocol involves stimulating endogenous stem cells through mitochondrial fusion and senolytic agents to expand stem cell pools and reduce senescent cell populations, using fullerenes and specific nutritional supplements to control mitochondrial morphology and promote ATP production, thereby reducing epigenetic age.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of stationary object

If telomeres are extended with supplements such as astragalus extracts containing cycloastragenol, then the Hayflick crisis is delayed and short-term health benefits are provided, but cells continue to age epigenetically and become ever more dysfunctional

Engineering Contradiction:

Improvecell division capacityVSAvoidcellular function

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

Instead of trying to extend telomeres to delay cellular expiration, the patent inverts the approach by using senolytic agents to remove senescent cells and stimulate stem cell proliferation. This reverses the aging process by replacing old dysfunctional cells with young functional ones, rather than attempting to extend the life of aging cells.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent extracts and removes senescent cells from the tissue using senolytic agents that selectively induce apoptosis in senescent cells while sparing healthy cells. This extraction of harmful senescent cells eliminates the source of epigenetic dysfunction and inflammation without affecting the underlying DNA or forcing aging cells to continue dividing.

Inventive Principle:

Principle #2Taking out (Extraction)

2Quantity of substance

If senescent cells are allowed to accumulate with age, then the body's natural clearance processes fail to keep up, but this creates inflammation and drives neighboring cells into senescence through the senescence-associated secretory phenotype

Engineering Contradiction:

Improvesenescent cell populationVSAvoidinflammation and senescence signaling

Core Design Contradiction:

Quantity of substanceVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful senescent cells into a beneficial process by using senolytic agents to selectively eliminate them. The senolytic compounds transform the persistent harmful presence of senescent cells into a controlled removal process, reducing inflammation and preventing the spread of senescence to neighboring cells through the SASP.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

Senolytic agents act as intermediaries that selectively target and eliminate senescent cells without directly affecting healthy cells or the underlying DNA. These agents mediate the removal of harmful senescent cells through apoptosis induction, clearing the tissue of inflammatory sources while preserving functional cells.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If stem cell pools are not effectively managed, then endogenous stem cells cannot replace somatic cells reaching expiration dates, but this leads to a Hayflick crisis and organism death

Engineering Contradiction:

Improvestem cell replacement rateVSAvoidorganism survival

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies preliminary action by using senolytic treatments to clear senescent cells before they can accumulate and cause widespread dysfunction. By proactively removing senescent cells and stimulating stem cell proliferation, the system prevents the Hayflick crisis from developing rather than responding to it after stem cell depletion occurs.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent enables the body's own stem cell pools to serve themselves by removing the inhibitory effect of senescent cells. Once senescent cells are cleared, endogenous stem cells can naturally proliferate and differentiate to replace aging somatic cells without external intervention, restoring the body's self-renewal capacity.

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach leads to a quasi-exponential increase in stem cell numbers, replacement of epigenetically old somatic cells with young ones, and a significant reduction in epigenetic age, potentially reversing the aging process and improving health outcomes.

Implementation Method 1

stimulating endogenous stem cells through mitochondrial fusion and senolytic agents to expand stem cell pools

Methodology Applied

Scientific EffectMitochondrial fusion:

Implementation Method 2

using fullerenes and specific nutritional supplements to control mitochondrial morphology and promote ATP production

Methodology Applied

Scientific EffectATP production:

Data Source

PatentUS11317646B2Methods and compositions for rapidly decreasing epigenetic age and restoration of more youthful function

Publication Date: 2022.05.03 DISCHLER LOUIS

AI summary

Disclosed are methods and compositions of reducing the epigenetic age of mammalian organism, especially an adult human of geriatric age. The methods provide for the proliferation of endogenous stem cells using mitochondrial fusion and a UCP2 blocker or other stimulants; supplying stem cells with nutrition to prevent cell cycle arrest; and removal of senescent somatic cells using senolytic treatments. The proliferation of endogenous neural stem cells after plaque removal for the treatment of Alzheimer's is also disclosed.